Overnight versus progressive conversion of multiple daily dose enteric-coated divalproex [valproate semisodium] extended release: Which strategy is better tolerated by patients with intellectual disabilities?

Trial Profile

Overnight versus progressive conversion of multiple daily dose enteric-coated divalproex [valproate semisodium] extended release: Which strategy is better tolerated by patients with intellectual disabilities?

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Valproate semisodium (Primary)
  • Indications Behavioural disorders; Bipolar disorders; Epilepsy
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Oct 2009 Results published in the Journal of Clinical Psychopharmacology.
    • 30 Nov 2007 Results have been reported (1088717)
    • 30 Nov 2007 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top